Pyxis Oncology Future Growth

Future criteria checks 2/6

Pyxis Oncology's earnings are forecast to decline at 9.8% per annum while its annual revenue is expected to grow at 58.3% per year. EPS is expected to grow by 8.1% per annum.

Key information

-9.8%

Earnings growth rate

8.1%

EPS growth rate

Biotechs earnings growth	24.0%
Revenue growth rate	58.3%
Future return on equity	n/a
Analyst coverage	Low
Last updated	12 Apr 2024

Recent future growth updates

Recent updates

Pyxis Oncology: Data Arriving Later Than Expected, But May Be Worth The Wait

Mar 28

Pyxis Oncology: Making A Bold Acquisition Move, But It's Not A Convincing Thesis

Jan 18

Earnings and Revenue Growth Forecasts

NasdaqGS:PYXS - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	9	-99	N/A	N/A	3
12/31/2025	1	-76	N/A	-53	4
12/31/2024	5	-43	N/A	-49	4
12/31/2023	N/A	-74	-77	-71	N/A
9/30/2023	N/A	-94	-81	-73	N/A
6/30/2023	N/A	-99	-89	-76	N/A
3/31/2023	N/A	-109	-99	-88	N/A
12/31/2022	N/A	-121	-96	-89	N/A
9/30/2022	N/A	-101	-89	-84	N/A
6/30/2022	N/A	-88	-71	-71	N/A
3/31/2022	N/A	-71	-45	-44	N/A
12/31/2021	N/A	-76	-36	-35	N/A
9/30/2021	N/A	-64	-27	-26	N/A
6/30/2021	N/A	-53	-22	-22	N/A
3/31/2021	N/A	-47	-28	-27	N/A
12/31/2020	N/A	-13	-12	-10	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: PYXS is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: PYXS is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: PYXS is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: PYXS's revenue (58.3% per year) is forecast to grow faster than the US market (8.3% per year).

High Growth Revenue: PYXS's revenue (58.3% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if PYXS's Return on Equity is forecast to be high in 3 years time

Pyxis Oncology Future Growth

Future criteria checks 2/6

Key information

Recent future growth updates

Price target decreased by 40% to US$6.00

Price target decreased by 19% to US$8.67

Price target decreased by 19% to US$8.67

Price target decreased to US$11.00

Recent updates

Pyxis Oncology, Inc., Annual General Meeting, Jun 11, 2024

Pyxis Oncology: Data Arriving Later Than Expected, But May Be Worth The Wait

New major risk - Shareholder dilution

Pyxis Oncology, Inc. Appoints Santhosh Palani to Its Board of Directors

Pyxis Oncology, Inc. announced that it expects to receive $49.999989 million in funding from Blue Owl Healthcare Opportunities, StemPoint Capital LP, Deep Track Capital, LP, Laurion Capital Management LP, Ridgeback Capital Management LLC and another investors

Pyxis Oncology: Making A Bold Acquisition Move, But It's Not A Convincing Thesis

Pyxis Oncology, Inc. Appoints Ken Kobayashi, M.D., F.A.C.P, as Chief Medical Officer

Price target decreased by 40% to US$6.00

CEO, President & Director recently sold US$63k worth of stock

Pyxis Oncology, Inc. (NasdaqGS:PYXS) completed the acquisition of Apexigen, Inc. (NasdaqCM:APGN) from entities associated with Pfizer Inc. (NYSE:PFE), Lincoln Park Capital, LLC, managed by Laurion Capital Management LP, Bayer World Investments B.V. and others.

Price target decreased by 19% to US$8.67

High number of new and inexperienced directors

Price target decreased by 19% to US$8.67

Chief Medical Officer notifies of intention to sell stock

New minor risk - Market cap size

Pyxis Oncology, Inc. Advances Pyx-106 and PYX-201 Clinical Programs

Pyxis Oncology, Inc. (NasdaqGS:PYXS) entered into a definitive agreement to acquire Apexigen, Inc. (NasdaqCM:APGN) for $15.9 million.

Pyxis Oncology, Inc. (NasdaqGS : PYXS) entered into a definitive agreement to acquire Apexigen, Inc. (NasdaqCM : APGN) for $15.9 million.

Will Pyxis Oncology (NASDAQ:PYXS) Spend Its Cash Wisely?

Price target decreased to US$11.00

High number of new and inexperienced directors

Here's Why We're Watching Pyxis Oncology's (NASDAQ:PYXS) Cash Burn Situation

Pyxis Oncology, Inc. Appoints Rachel Humphrey to Its Board of Directors

Pyxis Oncology GAAP EPS of -$0.79 beats by $0.06

Pyxis Oncology, Inc. Appoints Jitendra Wadhane as Chief Accounting Officer and Principal Accounting Office

Pyxis Oncology, Inc.(NasdaqGS:PYXS) dropped from Russell 2500 Value Index

High number of new and inexperienced directors

High number of new and inexperienced directors

Pyxis Oncology Announces Leadership Changes

We're Hopeful That Pyxis Oncology (NASDAQ:PYXS) Will Use Its Cash Wisely

High number of new and inexperienced directors

Independent Director recently bought US$94k worth of stock

Independent Director recently bought US$200k worth of stock

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies